본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

The Journal of antimicrobial chemotherapy v.72 no.2, 2017년, pp.490 - 495   SCI SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients

Bouazza, Naim (EA7323, Universitéôé ); Cressey, Tim R. (Paris Descartes, Sorbonne Paris Citéôéé, Paris, France ); Foissac, Frantz (Program for HIV Prevention and Treatment (PHPT/IRD UMI 174), Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand ); Bienczak, Andrzej (EA7323, Universitéôé ); Denti, Paolo (Paris Descartes, Sorbonne Paris Citéôéé, Paris, France ); McIlleron, Helen (Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa ); Burger, David (Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa ); Penazzato, Martina (Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa ); Lallemant, Marc (Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands ); Capparelli, Edmund V. (HIV Department, World Health Organization, Geneva, Switzerland ); Treluyer, Jean-Marc (Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland ); Urien, Saik (University of California San Diego, La Jolla, C );
  • 초록  

    Background Child-friendly, low-cost, solid, oral fixed-dose combinations (FDCs) of efavirenz with lamivudine and abacavir are urgently needed to improve clinical management and drug adherence for children. Methods Data were pooled from several clinical trials and therapeutic drug monitoring datasets from different countries. The number of children/observations was 505/3667 for efavirenz. Population pharmacokinetic analyses were performed using a non-linear mixed-effects approach. For abacavir and lamivudine, data from 187 and 920 subjects were available (population pharmacokinetic models previously published). Efavirenz/lamivudine/abacavir FDC strength options assessed were (I) 150/75/150, (II) 120/60/120 and (III) 200/100/200 mg. Monte Carlo simulations of the different FDC strengths were performed to determine the optimal dose within each of the WHO weight bands based on drug efficacy/safety targets. Results The probability of being within the target efavirenz concentration range 12 h post-dose (1–4 mg/L) varied between 56% and 60%, regardless of FDC option. Option I provided a best possible balance between efavirenz treatment failure and toxicity risks. For abacavir and lamivudine, simulations showed that for option I >75% of subjects were above the efficacy target. Conclusions According to simulations, a paediatric efavirenz/lamivudine/abacavir fixed-dose formulation of 150 mg efavirenz, 75 mg lamivudine and 150 mg abacavir provided the most effective and safe concentrations across WHO weight bands, with the flexibility of dosage required across the paediatric population.


 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기